ReWalk Robotics (NASDAQ: RWLK) recently received a buy rating from HC Wainwright in a research note released on Wednesday. The medical device company was also given a price target of $3.00. HC Wainwright’s positive outlook reflects their belief in ReWalk Robotics’ potential for growth and success in the market.
According to HC Wainwright’s estimates, ReWalk Robotics is expected to report negative earnings for Q4 2023, with an EPS of ($0.13). However, they anticipate a turnaround in FY2023, with estimated earnings of ($0.38) EPS. The research note also includes projections for the future, with estimates for Q1 and Q2 of 2024 showing further improvement in earnings.
The buy rating from HC Wainwright is a positive indicator for ReWalk Robotics, as it suggests that the company is well-positioned for future success. This aligns with the recent coverage initiated by StockNews.com, which also expressed confidence in the company’s potential for growth.
ReWalk Robotics has shown strong performance in the market, with its stock opening at $0.75 on Wednesday. The company has a 52-week low of $0.56 and a 52-week high of $0.98. With a market capitalization of $45.02 million, ReWalk Robotics continues to attract attention from investors.
In terms of insider activity, major shareholder Global Fund LP Lind II recently purchased 5,031,200 shares of ReWalk Robotics stock. This acquisition further emphasizes confidence in the company’s potential and its ability to deliver value to investors.
Institutional investors have also taken notice of ReWalk Robotics’ potential, with Mercer Global Advisors Inc. ADV and Renaissance Technologies LLC increasing their stakes in the company. This demonstrates the wider market’s belief in the growth prospects of ReWalk Robotics.
As a medical device company, ReWalk Robotics focuses on designing, developing, and commercializing robotic exoskeletons for individuals with mobility impairments or other medical conditions. Its products, such as ReWalk Personal and ReWalk Rehabilitation, cater to individuals with spinal cord injuries and lower limb disabilities.
In conclusion, ReWalk Robotics’ buy rating from HC Wainwright showcases the market’s confidence in the company’s potential for growth and success. The positive outlook reflects the belief that the company’s innovative medical devices will continue to make a positive impact in the healthcare industry.
Q: What is ReWalk Robotics’ current stock performance?
A: ReWalk Robotics’ stock opened at $0.75 on Wednesday, with a 52-week low of $0.56 and a 52-week high of $0.98.
Q: Who recently purchased shares of ReWalk Robotics?
A: Major shareholder Global Fund LP Lind II recently acquired 5,031,200 shares of ReWalk Robotics.
Q: Which institutional investors have shown interest in ReWalk Robotics?
A: Mercer Global Advisors Inc. ADV and Renaissance Technologies LLC have increased their stakes in ReWalk Robotics.